Megalotect Cp

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect Cp, is an immunoglobulin presented as a sterile intravenous solution for intravenous use. It supplies passive immunity by delivering antibodies that neutralize human cytomegalovirus, helping to prevent or treat CMV infection in transplant recipients and other immunocompromised patients.

GNH USA supplies Megalotect Cp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable cold‑chain logistics for this biologic product.

Megalotect Cp, a cytomegalovirus‑specific immunoglobulin, is used to provide passive immunity against human cytomegalovirus (HCMV) infections. - Solid organ transplant prophylaxis: reduces the incidence of CMV disease in recipients of kidney, liver, heart or lung transplants. - Bone marrow transplant treatment: aids in the management of active CMV disease in hematopoietic stem cell transplant patients. - Immunocompromised patient prophylaxis: offers protection against CMV reactivation in individuals with severe immune deficiency.

Megalotect Cp may be associated with infusion‑related reactions and immune‑mediated adverse events.

Common Side Effects: - Fever - Chills - Headache - Nausea

Serious or Rare Side Effects: - Anaphylaxis - Aseptic meningitis - Renal impairment

Before administering Megalotect Cp, consider the following precautions to ensure safe use. - Assess CMV serostatus: verify donor and recipient serology to determine need for prophylaxis. - Monitor infusion reactions: observe patient during and after infusion for fever, chills, or hypotension. - Contraindicate in IgA deficiency: avoid use in patients with known severe IgA deficiency due to risk of anaphylaxis. - Use cautiously in renal impairment: adjust volume and monitor renal function during therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Megalotect Cp can interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid): - Concurrent administration of other blood products: may increase risk of volume overload and circulatory complications. - Co‑administration with live viral vaccines: passive antibodies can diminish vaccine efficacy. - Use with monoclonal antibodies targeting CMV: potential antagonistic effect on therapeutic activity.

Moderate Interactions (Monitor Closely): - Combination with systemic steroids: may mask infusion‑related symptoms, requiring closer observation. - Concomitant use of diuretics: monitor fluid balance and electrolytes due to added volume load. - Co‑administration with antiviral agents such as ganciclovir: may have additive antiviral effects, necessitating viral load monitoring.